Research Analysts’ Weekly Ratings Updates for Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (NASDAQ: RARE) recently received a number of ratings updates from brokerages and research firms:

• 9/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Barclays PLC from $32.00 to $35.00. They now have an “overweight” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Citigroup Inc. from $31.00 to $32.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $37.00 to $39.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Cantor Fitzgerald from $33.00 to $39.00. They now have an “overweight” rating on the stock.
• 9/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $19.00. They now have a “neutral” rating on the stock.
• 9/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Barclays PLC from $43.00 to $32.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Royal Bank Of Canada from “moderate buy” to “hold”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Jefferies Financial Group Inc. from $77.00 to $28.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Citigroup Inc. from $58.00 to $28.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by TD Cowen from $49.00 to $18.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Bank of America Corporation from “buy” to “neutral”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wedbush from $30.00 to $23.00. They now have a “neutral” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Canaccord Genuity Group Inc. from $83.00 to $37.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by William Blair from “outperform” to “market perform”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Cantor Fitzgerald from $103.00 to $33.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by HC Wainwright from $50.00 to $25.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $16.00 price target on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Robert W. Baird from “outperform” to “neutral”. They now have a $16.00 price target on the stock, down from $40.00.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by JPMorgan Chase & Co. from “overweight” to “neutral”. They now have a $36.00 price target on the stock, down from $80.00.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $18.00 price target on the stock, down from $50.00.
• 8/28/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $46.00 to $50.00. They now have an “overweight” rating on the stock.
• 8/25/2026 – Ultragenyx Pharmaceutical had its price target raised by JPMorgan Chase & Co. from $75.00 to $80.00. They now have an “overweight” rating on the stock.
• 8/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $67.00 to $74.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $81.00 to $83.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Citigroup Inc. from $45.00 to $58.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $45.00 to $46.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Cantor Fitzgerald from $96.00 to $103.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 8/8/2026 – Ultragenyx Pharmaceutical was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/5/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a “buy” rating on the stock.

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.